Ali İhsan PARLAR, Seyhan BABAROĞLU, Ayşen AKSÖYEK, Mehtap TEMURTÜRKAN, Ahmet Tulga ULUS, Ufuk TÜRÜN, Ferit ÇİÇEKÇİOĞLU, Salih Fehmi KATIRCIOĞLU

Fifteen years survival without anticoagulation after mechanical tricuspid valve replacement: A case report

İzole triküspit kapak değişimi yaygın olarak yapılan bir ameliyat olmayıp, mekanik veya biyolojik protez kapak arasındaki tercih tartışmalıdır. Mekanik protezler kullanıldığında antikoagülan tedavisi zorunludur. Bu yazıda, Björk-Shiley protezi ile triküspit kapak değişimini takiben 15 yıl antikoagülasyon olmadan sağ kalan 21 yaşında kadın hasta bildirildi. Sonuçta mekanik kapak tıkandı ve triküspit kapak, St. Jude Medical trileaflet biyoprotez kapak ile değiştirildi.

Mekanik triküspit kapak değişimi sonrası antikoagülasyonsuz 15 yıllık sağkalım: Olgu sunumu

Isolated tricuspid valve replacement is not a common operation and the choice between mechanical and biologic prostheses remains controversial. When mechanical prosthesis are used, anticoagulant therapy is mandatory. In this article, we report a 21-years-old female patient who survived 15-years without anticoagulation following tricuspid valve replacement with a Björk-Shiley prosthesis. Ultimately the mechanical valve was stuck and we replaced the tricuspid valve with a St. Jude Medical trileaflet bioprosthesis.

PDF

___

1) Scully HE, Armstrong CS. Tricuspid valve replacement. Fifteen years of experience with mechanical prostheses and bioprostheses. J Thorac Cardiovasc Surg 1995;109:1035-41.
2) Jegaden O, Perinetti M, Barthelet M, Vedrinne C, Delahaye F, Montagna P, et al. Long-term results of porcine bioprostheses in the tricuspid position. Eur J Cardiothorac Surg 1992; 6:256-60.
3) Iscan ZH, Vural KM, Bahar I, Mavioglu L, Saritas A. What to expect after tricuspid valve replacement? Long-term results. Eur J Cardiothorac Surg 2007;32:296-300.
4) Mangoni AA, DiSalvo TG, Vlahakes GJ, Polanczyk CA, Fifer MA. Outcome following isolated tricuspid valve replacement. Eur J Cardiothorac Surg 2001;19:68-73.
5) Bourdillon PD, Sharratt GP. Malfunction of Björk-Shiley valve prosthesis in tricuspid position. Br Heart J 1976; 38:1149-53.
6) Wellens F, Jacques G. Tricuspid valve replacement. Cardiovasc Clin 1987;17:111-5.
7) Singh AK, Christian FD, Williams DO, Georas CS, Riley RR, Nanian KB, et al. Follow-up assessment of St. Jude Medical prosthetic valve in the tricuspid position: clinical and hemodynamic results. Ann Thorac Surg 1984;37:324-7.
8) McGrath LB, Chen C, Bailey BM, Fernandez J, Laub GW, Adkins MS. Early and late phase events following bioprosthetic tricuspid valve replacement. J Card Surg 1992;7:245-53.
9) Cohen SR, Silver MA, McIntosh CL, Roberts WC. Comparison of late (62 to 140 months) degenerative changes in simultaneously implanted and explanted porcine (Hancock) bioprostheses in the tricuspid and mitral valve positions in six patients. Am J Cardiol 1984;53:1599-602.
10) Kawachi Y, Tominaga R, Hisahara M, Nakashima A, Yasui H, Tokunaga K. Excellent durability of the Hancock porcine bioprosthesis in the tricuspid position. A sixteen-year followup study. J Thorac Cardiovasc Surg 1992;104:1561-6.
11) Carrier M, Hébert Y, Pellerin M, Bouchard D, Perrault LP, Cartier R, et al. Tricuspid valve replacement: an analysis of 25 years of experience at a single center. Ann Thorac Surg 2003;75:47-50.